Analysis of risk factors for depression in Alzheimer's disease patients

被引:12
作者
Yang, Hai [1 ]
Hong, Wenjuan [2 ]
Chen, Le [2 ]
Tao, Yong [1 ]
Peng, Zeyan [1 ]
Zhou, Huadong [1 ]
机构
[1] Army Mil Med Univ, Daping Hosp, Dept Neurol, Chongqing 400042, Peoples R China
[2] Bengbu Med Coll, Grad Sch, Bengbu City, Peoples R China
基金
中国国家自然科学基金;
关键词
Alzheimer's disease; depression; glycosylated hemoglobin; anti-diabetes drugs; LATE-LIFE DEPRESSION; INSULIN-RESISTANCE; DOUBLE-BLIND; DEMENTIA; SYMPTOMS; BRAIN; EPIDEMIOLOGY; BIOMARKERS; DIAGNOSIS; COGNITION;
D O I
10.1080/00207454.2020.1730369
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Purpose: Depression, which affects about 52% of Alzheimer's disease (AD) patients, can worsen cognitive impairment and increase mortality and suicide rates. We hope to provide clinical evidence for the prevention and treatment of depression in AD patients by investigating related risk factors of depression in AD patients. Methods: 158 AD inpatients of the Department of Neurology, Daping Hospital from September 2017 to March 2019 were enrolled. General information, laboratory tests, cognitive and emotional function assessments of the inpatients were collected. Logistic regression was used to analyze the risk factors of depression in AD patients, and the relationship between 17 Hamilton depression scale scores and HbA1c levels in AD patients was further analyzed. Results: The prevalence of age, gender, hypertension, hyperlipidemia, Type 2 diabetes mellitus (T2DM), and white matter lesions (WML) in the AD with depression group was significantly different from without depression group. Hypertension, T2DM, and WML are independent risk factors for depression in AD patients. The depression scores of AD patients with HbA1c>6.5% were significantly higher than AD patients with HbA1c <= 6.5%, and there were significant difference in depression scale scores between using anti-diabetes drugs group and not using anti-diabetes drugs group whose HbA1c level is >6.5%, while no difference in depression scores between using anti-diabetes drugs group and not using anti-diabetes drugs group whose HbA1c level is <= 6.5%. Conclusion: T2DM is an independent risk factor for AD patients with depression. Increased HbA1c levels aggravate depression in AD patients, and controlling HbA1c levels and anti-diabetes drugs can reduce the severity of depression in AD patients.
引用
收藏
页码:1136 / 1141
页数:6
相关论文
共 41 条
[1]   Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial [J].
Banerjee, Sube ;
Hellier, Jennifer ;
Dewey, Michael ;
Romeo, Renee ;
Ballard, Clive ;
Baldwin, Robert ;
Bentham, Peter ;
Fox, Chris ;
Holmes, Clive ;
Katona, Cornelius ;
Knapp, Martin ;
Lawton, Claire ;
Lindesay, James ;
Livingston, Gill ;
McCrae, Niall ;
Moniz-Cook, Esme ;
Murray, Joanna ;
Nurock, Shirley ;
Orrell, Martin ;
O'Brien, John ;
Poppe, Michaela ;
Thomas, Alan ;
Walwyn, Rebecca ;
Wilson, Kenneth ;
Burns, Alistair .
LANCET, 2011, 378 (9789) :403-411
[2]   An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Aβ oligomers [J].
Bomfim, Theresa R. ;
Forny-Germano, Leticia ;
Sathler, Luciana B. ;
Brito-Moreira, Jordano ;
Houzel, Jean-Christophe ;
Decker, Helena ;
Silverman, Michael A. ;
Kazi, Hala ;
Melo, Helen M. ;
McClean, Paula L. ;
Holscher, Christian ;
Arnold, Steven E. ;
Talbot, Konrad ;
Klein, William L. ;
Munoz, Douglas P. ;
Ferreira, Sergio T. ;
De Felice, Fernanda G. .
JOURNAL OF CLINICAL INVESTIGATION, 2012, 122 (04) :1339-1353
[3]   Epidemiology of Alzheimer's disease and other forms of dementia in China, 1990-2010: a systematic review and analysis [J].
Chan, Kit Yee ;
Wang, Wei ;
Wu, Jing Jing ;
Liu, Li ;
Theodoratou, Evropi ;
Car, Josip ;
Middleton, Lefkos ;
Russ, Tom C. ;
Deary, Ian J. ;
Campbell, Harry ;
Wang, Wei ;
Rudan, Igor .
LANCET, 2013, 381 (9882) :2016-2023
[4]   Convergent and divergent intranetwork and internetwork connectivity patterns in patients with remitted late-life depression and amnestic mild cognitive impairment [J].
Chen, Jiu ;
Shu, Hao ;
Wang, Zan ;
Zhan, Yafeng ;
Liu, Duan ;
Liao, Wenxiang ;
Xu, Lin ;
Liu, Yong ;
Zhang, Zhijun .
CORTEX, 2016, 83 :194-211
[5]   Insulin and neurodegenerative disease: shared and specific mechanisms [J].
Craft, S ;
Watson, GS .
LANCET NEUROLOGY, 2004, 3 (03) :169-178
[6]   Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Disease Biomarkers: A Pilot Clinical Trial [J].
Craft, Suzanne ;
Claxton, Amy ;
Baker, Laura D. ;
Hanson, Angela J. ;
Cholerton, Brenna ;
Trittschuh, Emily H. ;
Dahl, Deborah ;
Caulder, Erin ;
Neth, Bryan ;
Montine, Thomas J. ;
Jung, Youngkyoo ;
Maldjian, Joseph ;
Whitlow, Christopher ;
Friedman, Seth .
JOURNAL OF ALZHEIMERS DISEASE, 2017, 57 (04) :1325-1334
[7]   Research criteria for the diagnosis of Alzheimer"s disease: revising the NINCDS-ADRDA criteria [J].
Dubois, Bruno ;
Feldman, Howard H. ;
Jacova, Claudia ;
Dekosky, Steven T. ;
Barberger-Gateau, Pascale ;
Cummings, Jeffrey ;
Delocourte, Andre ;
Galasko, Douglas ;
Gauthier, Serge ;
Jicha, Gregory ;
Meguro, Kenichi ;
O'Brien, John ;
Pasquier, Florence ;
Robert, Philippe ;
Rossor, Martin ;
Solloway, Steven ;
Stern, Yaakov ;
Visser, Pieter J. ;
Scheltens, Philip .
LANCET NEUROLOGY, 2007, 6 (08) :734-746
[8]   ATP-sensitive potassium-channel inhibitor glibenclamide attenuates HPA axis hyperactivity, depression- and anxiety-related symptoms in a rat model of Alzheimer's disease [J].
Esmaeili, Mohammad Hossein ;
Bahari, Behnam ;
Salari, Ali-Akbar .
BRAIN RESEARCH BULLETIN, 2018, 137 :265-276
[9]   Depression and Diabetes Treatment Nonadherence: A Meta-Analysis [J].
Gonzalez, Jeffrey S. ;
Peyrot, Mark ;
McCarl, Lauren A. ;
Collins, Erin Marie ;
Serpa, Luis ;
Mimiaga, Matthew J. ;
Safren, Steven A. .
DIABETES CARE, 2008, 31 (12) :2398-2403
[10]   Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes [J].
Gupta, Amit ;
Bisht, Bharti ;
Dey, Chinmoy Sankar .
NEUROPHARMACOLOGY, 2011, 60 (06) :910-920